bioAffinity Technologies, Inc. (Nasdaq: BIAF) announced that stockholders approved an amendment to the Company's Certificate of Incorporation at a Special Meeting held on November 20, 2026. The amendment, filed with the Secretary of State of Delaware, reduces the total number of authorized shares of common stock, par value $0.007 per share, from 350,000,000 shares to 200,000,000 shares. The Charter Amendment became effective immediately upon filing.
The Special Meeting was held following a record date of September 23, 2026, during which 1,166,625 shares of Common Stock were outstanding and entitled to vote. In addition to the reduction of authorized shares, stockholders approved several other proposals related to warrant exercises and future offerings.
Specifically, stockholders approved the issuance of up to 1,128,272 shares of Common Stock issuable upon exercise of warrants from a private placement closing on August 14, 2026. They also approved the issuance of up to 980,072 shares of Common Stock issuable upon exercise of warrants from a private placement closing on October 8, 2026. Furthermore, stockholders approved the issuance of securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d).
The voting results for the proposal to decrease authorized shares were as follows: 319,130 votes For, 149,445 votes Against, and 57,191 abstentions. The adjournment proposal, which would have allowed for further solicitation if votes were insufficient, was also approved with 308,230 votes For and 159,496 votes Against.